#United States #Dallas #gene therapy #Nanoscope Therapeutics #Ramesh Arjunji

Nanoscope Therapeutics Welcomes Ramesh Arjunji as New Executive Vice President

In a significant strategic move, Nanoscope Therapeutics Inc., a biotech company focused on innovative gene therapies for retinal diseases, has brought on board Ramesh Arjunji, PhD, as its Executive Vice President of Value and Access. This announcement was made on March 5, 2025, highlighting the company's commitment to improving market access for its groundbreaking treatments.

Background of Ramesh Arjunji

Dr. Arjunji is well-regarded in the biopharmaceutical sector, boasting an impressive background that spans various leadership roles across commercialization, research and development, medical affairs, and business development. His experience encompasses multiple therapeutic areas including ophthalmology, neurology, oncology, and immunology, making him a valuable asset to Nanoscope.

Sulagna Bhattacharya, CEO and co-founder of Nanoscope, expressed excitement about Dr. Arjunji's experience. "Ramesh has been pivotal in leading market access strategies for some of the most successful gene therapies to date. His expertise will greatly benefit our mission as we prepare to launch MCO-010 for patients suffering from retinitis pigmentosa," she stated.

Dr. Arjunji’s Vision

When discussing his new role, Dr. Arjunji relayed his enthusiasm for spearheading initiatives that ensure effective access to gene therapies for those in need. "I have had the privilege of guiding several gene therapies to the market, and I am committed to leveraging my knowledge to help Nanoscope achieve remarkable milestones in providing life-changing treatments to patients facing visual impairment," he shared.

Previous Achievements

Before joining Nanoscope, Dr. Arjunji held the position of Senior Vice President, Global Value and Access at Krystal Biotech. He also contributed his expertise at SSI Strategy as Vice President, where he advised on evidence generation strategies. His career trajectory includes significant roles in organizations renowned for their contributions to gene therapy, such as Avrobio and AveXis/Novartis Gene Therapies. His leadership in developing market strategies for ZOLGENSMA, the gene therapy for spinal muscular atrophy, underlines his expertise in the field.

Nanoscope Therapeutics and Its Mission

Nanoscope is at the forefront of developing gene therapies that restore sight in patients affected by hereditary retinal diseases. The company is focused on pioneering optogenetic therapies, having recently completed a significant clinical trial (the RESTORE Phase 2b) that aims to submit a Biologics License Application (BLA) for its treatment, MCO-010, by the first quarter of 2025. This therapy targets retinitis pigmentosa, a condition that currently has no cure.

In addition to the promising results from their recent trials, Nanoscope has also been granted FDA Fast Track and orphan drug designations for MCO-010, emphasizing the urgency and potential impact of their innovative solutions. The firm plans to initiate further clinical trials, aimed at expanding their therapeutic offerings, including those for Stargardt disease and Leber Congenital Amaurosis.

The Road Ahead

As Nanoscope Therapeutics gears up for crucial developments under Dr. Arjunji’s leadership, the biotech community watches closely. With a robust pipeline and a commitment to enhancing patient access to treatments that could potentially revolutionize the standard of care in retinal diseases, the company is poised for significant advancements in the coming years.

In summary, the appointment of Dr. Ramesh Arjunji as Executive Vice President of Value and Access heralds a new chapter for Nanoscope, aligning their expertise in gene therapy with a strategic focus on market access, which is vital for reaching patients who need these revolutionary treatments the most.